Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Industry Shakeup: Former FDA Official Joins Eli Lilly, Leadership Changes at OSE and TRIO

Industry Shakeup: Former FDA Official Joins Eli Lilly, Leadership Changes at OSE and TRIO

In a series of significant leadership changes, the pharmaceutical industry sees notable shifts as key figures move between regulatory bodies and private sector roles. These developments promise to reshape the landscape of drug discovery and development, particularly in the realms of infectious diseases and cancer research.

NoahAI News10/10/2025
AviadoBio Expands Gene Therapy Portfolio with $413M Chinese Deal

AviadoBio Expands Gene Therapy Portfolio with $413M Chinese Deal

England-based AviadoBio has secured an option to license a promising gene therapy for rare eye diseases from Chinese biotech UgeneX Therapeutics. The deal, potentially worth up to $413 million, marks a significant expansion of AviadoBio's gene therapy pipeline and highlights growing cross-border collaborations in the biotechnology sector.

NoahAI News10/9/2025
Oncology Job Market Heats Up as Industry Forecasts Significant Growth

Oncology Job Market Heats Up as Industry Forecasts Significant Growth

The global oncology market is poised for substantial expansion, with projections indicating a near doubling by 2034, according to Towards Healthcare. This growth forecast is driving a surge in job opportunities across the pharmaceutical and biotechnology sectors, particularly in oncology-related roles. Industry experts suggest that oncology remains a "safe bet" for job seekers, given the constant need for innovation in cancer treatment.

NoahAI News10/9/2025
Catalent Expands ADC Pipeline with $10M Lisata Deal, Exploring Novel Tumor-Targeting Approach

Catalent Expands ADC Pipeline with $10M Lisata Deal, Exploring Novel Tumor-Targeting Approach

Catalent, a leading contract development and manufacturing organization (CDMO), has inked a $10 million biobucks agreement with Lisata Therapeutics to evaluate the potential of certepetide in antibody-drug conjugate (ADC) development. This move marks Catalent's latest foray into the burgeoning ADC space and underscores the growing interest in novel approaches to targeted cancer therapies.

NoahAI News10/9/2025
FDA Breakthrough Therapy Designation Proves Highly Effective, New Analysis Shows

FDA Breakthrough Therapy Designation Proves Highly Effective, New Analysis Shows

The U.S. Food and Drug Administration's (FDA) Breakthrough Therapy Designation (BTD) program has demonstrated significant success in expediting the approval of drugs for serious conditions, according to a new analysis by Jefferies. The report, which examined 599 BTDs granted between 2013 and 2025, reveals that approximately 72% of drugs receiving this designation went on to win approval, with an additional 13% still awaiting decisions.

NoahAI News10/9/2025
FDA Breakthrough Therapy Designation Proves Highly Successful for Drug Approvals

FDA Breakthrough Therapy Designation Proves Highly Successful for Drug Approvals

The U.S. Food and Drug Administration's (FDA) Breakthrough Therapy Designation (BTD) program has demonstrated significant success in expediting the approval of drugs for serious conditions, according to a recent analysis by Jefferies. The report, which examined 599 BTDs granted between 2013 and 2025, reveals that approximately 72% of drugs receiving this designation went on to win approval, with an additional 13% still awaiting decision.

NoahAI News10/9/2025
Arthrosi Secures $153M for Next-Generation Gout Treatment

Arthrosi Secures $153M for Next-Generation Gout Treatment

Arthrosi Therapeutics, a San Diego-based biotechnology startup, has closed a $153 million Series E financing round to accelerate the development of a potentially groundbreaking gout medication. The funding, led by Prime Eight Capital, marks a significant step forward in the pursuit of more effective treatments for this common form of arthritis.

NoahAI News10/9/2025
Sanofi Challenges Novartis in Radioligand Therapy with Promising Pancreatic Tumor Data

Sanofi Challenges Novartis in Radioligand Therapy with Promising Pancreatic Tumor Data

Sanofi and partner Orano Med have made a significant stride in the field of radioligand therapy, potentially positioning themselves as formidable competitors to Novartis, the current leader in this therapeutic modality. The companies recently announced positive results from their Phase II ALPHAMEDIX-02 study, evaluating the targeted radioligand therapy AlphaMedix in patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

NoahAI News10/9/2025
Zenas BioPharma Strikes $2B+ Deal with InnoCare, Bolstering Autoimmune Portfolio

Zenas BioPharma Strikes $2B+ Deal with InnoCare, Bolstering Autoimmune Portfolio

Zenas BioPharma has entered into a potentially $2 billion-plus licensing agreement with Chinese firm InnoCare Pharma, significantly expanding its autoimmune disease pipeline. The deal, announced on Wednesday, centers around three key assets, including a late-stage multiple sclerosis (MS) treatment that could become a major player in the market.

NoahAI News10/9/2025
BD and Opentrons Labs Join Forces to Accelerate Disease Research and Drug Development

BD and Opentrons Labs Join Forces to Accelerate Disease Research and Drug Development

BD, a leading medtech company, and Opentrons Labworks, a specialist in lab automation, have announced a multi-year collaboration aimed at revolutionizing disease research and drug development processes. The partnership, revealed on October 8, 2025, will combine BD's advanced cell analysis capabilities with Opentrons' automation expertise to enhance single-cell multiomics experiments.

NoahAI News10/9/2025
Pharmaceutical Industry Faces Widespread Layoffs Amid Restructuring and Pipeline Shifts

Pharmaceutical Industry Faces Widespread Layoffs Amid Restructuring and Pipeline Shifts

The pharmaceutical and biotech sectors are experiencing a wave of workforce reductions as companies realign their priorities, streamline operations, and adapt to challenging market conditions. Major players and smaller biotechs alike are making difficult decisions to extend cash runways and focus resources on key programs.

NoahAI News10/9/2025
Venture Firms Invest $101M in Nilo Therapeutics, Pioneering Brain-Immune Axis Therapies

Venture Firms Invest $101M in Nilo Therapeutics, Pioneering Brain-Immune Axis Therapies

In a significant development for the biotech industry, Nilo Therapeutics has emerged from stealth mode with a substantial $101 million Series A financing round. The newly launched company aims to revolutionize the treatment of autoimmune and inflammatory diseases by targeting the intricate connection between the brain and the immune system.

NoahAI News10/9/2025
«1...464748...67»